SCHEMBL3335759

SCHEMBL3335759

CCCCOc1ccc(CCl)nc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP2D6 P10635 7/20 0.44
CYP3A4 P08684 6/20 0.44
KDM4E B2RXH2 1/20 0.44
LTA4H P09960 3/20 0.43
CYP2C9 P11712 5/20 0.42
CYP2C19 P33261 4/20 0.42
CYP19A1 P11511 3/20 0.42
HRH3 Q9Y5N1 1/20 0.42
NR5A1 Q13285 1/20 0.42
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27347325 0.93 NR5A1 (0.49) NPC1RAB9ASMN1; SMN2HSD17B10KDM4E
Hydrochloric Acid SCHEMBL9265592 0.83 MAPT (0.50) NPC1RAB9ASMN1; SMN2KDM4ELTA4H
SCHEMBL3334122 0.81 LTA4H (0.46) NPC1RAB9ASMN1; SMN2HSD17B10CYP2D6
SCHEMBL16854785 0.80 NR5A1 (0.53) NPC1RAB9AHSD17B10KDM4ELTA4H
SCHEMBL28879067 0.79 NR5A1 (0.51) NPC1RAB9ASMN1; SMN2HSD17B10CYP3A4
SCHEMBL29987012 0.79 ALDH1A1 (0.44) RAB9ASMN1; SMN2CYP3A4KDM4EMAPT
SCHEMBL1844115 0.79 ALDH1A1 (0.44) RAB9ASMN1; SMN2CYP3A4KDM4EMAPT
SCHEMBL9334195 0.77 NR5A1 (0.54) NPC1RAB9ASMN1; SMN2HSD17B10LTA4H
Hydrochloric Acid SCHEMBL26125898 0.77 NR5A1 (0.50) NPC1RAB9ASMN1; SMN2HSD17B10CYP3A4
SCHEMBL3334096 0.77 KDM4E (0.43) NPC1RAB9ASMN1; SMN2HSD17B10CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144710-A1 Piperazine and Piperidine MGLUR5 Potentiators ASTRAZENECA AB (SE) 2010-06-10 US disclosed
US-20100144710-A1 Piperazine and Piperidine MGLUR5 Potentiators ASTRAZENECA AB (SE) 2010-06-10 US disclosed
CN-101679261-A Piperazine and piperidine mglur5 potentiators ASTRAZENECA AB 2010-03-24 CN disclosed
EP-2134687-A1 PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS AstraZeneca AB (SE) 2009-12-23 EP disclosed
WO-2008112440-A1 PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS ASTRAZENECA AB (SE) 2008-09-18 WO disclosed
WO-2008112440-A1 PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS ASTRAZENECA AB (SE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144710-A1 Piperazine and Piperidine MGLUR5 Potentiators GRM5, GRM1, GRM2 NPC1 1641/4885RAB9A 1841/4885SMN1; SMN2 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.